SANOFI-ADR (SNY)
US80105N1054 - ADR
SNY gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 205 industry peers in the Pharmaceuticals industry. SNY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. A decent growth rate in combination with a cheap valuation! Better keep an eye on SNY. SNY also has an excellent dividend rating. With these ratings, SNY could be worth investigating further for value and dividend and quality investing!.
1. Profitability
1.1 Basic Checks
SNY had positive earnings in the past year.
In the past year SNY had a positive cash flow from operations.
Each year in the past 5 years SNY has been profitable.
Each year in the past 5 years SNY had a positive operating cash flow.
1.2 Ratios
The Return On Assets of SNY (10.12%) is better than 93.17% of its industry peers.
The Return On Equity of SNY (17.47%) is better than 91.22% of its industry peers.
With an excellent Return On Invested Capital value of 15.53%, SNY belongs to the best of the industry, outperforming 92.20% of the companies in the same industry.
SNY had an Average Return On Invested Capital over the past 3 years of 6.95%. This is significantly below the industry average of 16.81%.
The last Return On Invested Capital (15.53%) for SNY is above the 3 year average (6.95%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.12% | ||
| ROE | 17.47% | ||
| ROIC | 15.53% |
ROA(3y)7.51%
ROA(5y)5.77%
ROE(3y)13.25%
ROE(5y)10.34%
ROIC(3y)6.95%
ROIC(5y)6.41%
1.3 Margins
SNY's Profit Margin of 18.09% is amongst the best of the industry. SNY outperforms 93.17% of its industry peers.
In the last couple of years the Profit Margin of SNY has declined.
The Operating Margin of SNY (27.75%) is better than 94.15% of its industry peers.
SNY's Operating Margin has improved in the last couple of years.
The Gross Margin of SNY (70.31%) is better than 78.54% of its industry peers.
SNY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.75% | ||
| PM (TTM) | 18.09% | ||
| GM | 70.31% |
OM growth 3Y7.11%
OM growth 5Y2.17%
PM growth 3Y36.08%
PM growth 5Y-4.51%
GM growth 3Y0.81%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
SNY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, SNY has about the same amount of shares outstanding.
Compared to 5 years ago, SNY has about the same amount of shares outstanding.
The debt/assets ratio for SNY has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.07 indicates that SNY is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.07, SNY is in the better half of the industry, outperforming 77.07% of the companies in the same industry.
SNY has a debt to FCF ratio of 2.59. This is a good value and a sign of high solvency as SNY would need 2.59 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 2.59, SNY belongs to the best of the industry, outperforming 90.73% of the companies in the same industry.
SNY has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.22, SNY perfoms like the industry average, outperforming 43.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 2.59 | ||
| Altman-Z | 3.07 |
ROIC/WACC2.23
WACC6.96%
2.3 Liquidity
SNY has a Current Ratio of 1.21. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
SNY's Current ratio of 1.21 is on the low side compared to the rest of the industry. SNY is outperformed by 80.98% of its industry peers.
SNY has a Quick Ratio of 1.21. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.81, SNY is not doing good in the industry: 86.34% of the companies in the same industry are doing better.
SNY does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.81 |
3. Growth
3.1 Past
SNY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.29%, which is quite good.
Measured over the past years, SNY shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.29% on average per year.
SNY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.47%.
SNY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.62% yearly.
EPS 1Y (TTM)17.29%
EPS 3Y11.26%
EPS 5Y8.29%
EPS growth Q2Q0.58%
Revenue 1Y (TTM)11.47%
Revenue growth 3Y6.45%
Revenue growth 5Y4.62%
Revenue growth Q2Q3.61%
3.2 Future
The Earnings Per Share is expected to grow by 7.20% on average over the next years.
The Revenue is expected to grow by 4.96% on average over the next years.
EPS Next Y0.51%
EPS Next 2Y4.07%
EPS Next 3Y7.15%
EPS Next 5Y7.2%
Revenue Next Year0.9%
Revenue Next 2Y3.09%
Revenue Next 3Y4.36%
Revenue Next 5Y4.96%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.03, the valuation of SNY can be described as very reasonable.
Based on the Price/Earnings ratio, SNY is valued cheaply inside the industry as 88.78% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 24.69. SNY is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 9.52, which indicates a very decent valuation of SNY.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 87.80% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 19.79. SNY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.03 | ||
| Fwd PE | 9.52 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SNY is valued cheaper than 95.12% of the companies in the same industry.
SNY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SNY is cheaper than 88.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.16 | ||
| EV/EBITDA | 5.21 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SNY does not grow enough to justify the current Price/Earnings ratio.
SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)19.59
PEG (5Y)1.21
EPS Next 2Y4.07%
EPS Next 3Y7.15%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.13%, SNY is a good candidate for dividend investing.
SNY's Dividend Yield is rather good when compared to the industry average which is at 4.65. SNY pays more dividend than 95.12% of the companies in the same industry.
SNY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.63.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.13% |
5.2 History
The dividend of SNY has a limited annual growth rate of 2.52%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
SNY has decreased its dividend in the last 3 years.
Dividend Growth(5Y)2.52%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
35.10% of the earnings are spent on dividend by SNY. This is a low number and sustainable payout ratio.
SNY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP35.1%
EPS Next 2Y4.07%
EPS Next 3Y7.15%
SANOFI-ADR
NASDAQ:SNY (11/30/2023, 4:35:24 PM)
After market: 46.75 0 (0%)46.75
+0.15 (+0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-27 2023-10-27/bmo
Earnings (Next)N/A N/A
Inst Owners10.07%
Inst Owner Change-0.75%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap117.24B
Analysts74
Price Target56.91 (21.73%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.13% |
Dividend Growth(5Y)2.52%
DP35.1%
Div Incr Years2
Div Non Decr Years2
Ex-Date05-30 2023-05-30 (1.9000852)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.8%
Min EPS beat(2)3.28%
Max EPS beat(2)6.32%
EPS beat(4)3
Avg EPS beat(4)3.78%
Min EPS beat(4)-0.71%
Max EPS beat(4)6.32%
Revenue beat(2)2
Avg Revenue beat(2)56.73%
Min Revenue beat(2)4.58%
Max Revenue beat(2)108.87%
Revenue beat(4)4
Avg Revenue beat(4)59.61%
Min Revenue beat(4)4.58%
Max Revenue beat(4)117.19%
PT rev (1m)-6.54%
PT rev (3m)-5.75%
EPS NQ rev (1m)0.23%
EPS NQ rev (3m)-0.47%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-0.04%
Revenue NQ rev (1m)0.85%
Revenue NQ rev (3m)-2.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.03 | ||
| Fwd PE | 9.52 | ||
| P/S | 1.52 | ||
| P/FCF | 13.16 | ||
| P/OCF | 10.4 | ||
| P/B | 1.47 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.21 |
EPS(TTM)4.66
EY9.97%
EPS(NY)4.91
Fwd EY10.5%
FCF(TTM)3.55
FCFY7.6%
OCF(TTM)4.5
OCFY9.62%
SpS30.72
BVpS31.81
TBVpS-0.53
PEG (NY)19.59
PEG (5Y)1.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.12% | ||
| ROE | 17.47% | ||
| ROCE | 19.35% | ||
| ROIC | 15.53% | ||
| ROICexc | 16.87% | ||
| ROICexgc | 82.79% | ||
| OM | 27.75% | ||
| PM (TTM) | 18.09% | ||
| GM | 70.31% | ||
| FCFM | 11.56% |
ROA(3y)7.51%
ROA(5y)5.77%
ROE(3y)13.25%
ROE(5y)10.34%
ROIC(3y)6.95%
ROIC(5y)6.41%
ROICexc(3y)8.01%
ROICexc(5y)7.28%
ROICexgc(3y)38.1%
ROICexgc(5y)32.67%
ROCE(3y)8.66%
ROCE(5y)8%
ROICexcg growth 3Y21.31%
ROICexcg growth 5Y10.17%
ROICexc growth 3Y11.04%
ROICexc growth 5Y2.97%
OM growth 3Y7.11%
OM growth 5Y2.17%
PM growth 3Y36.08%
PM growth 5Y-4.51%
GM growth 3Y0.81%
GM growth 5Y0.55%
F-Score7
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 2.59 | ||
| Debt/EBITDA | 0.71 | ||
| Cap/Depr | 62.74% | ||
| Cap/Sales | 3.08% | ||
| Interest Coverage | 43.06 | ||
| Cash Conversion | 44.82% | ||
| Profit Quality | 63.9% | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.81 | ||
| Altman-Z | 3.07 |
F-Score7
WACC6.96%
ROIC/WACC2.23
Cap/Depr(3y)60.69%
Cap/Depr(5y)50.45%
Cap/Sales(3y)5.21%
Cap/Sales(5y)5.19%
Profit Quality(3y)93.03%
Profit Quality(5y)115.45%
Growth
EPS 1Y (TTM)17.29%
EPS 3Y11.26%
EPS 5Y8.29%
EPS growth Q2Q0.58%
EPS Next Y0.51%
EPS Next 2Y4.07%
EPS Next 3Y7.15%
EPS Next 5Y7.2%
Revenue 1Y (TTM)11.47%
Revenue growth 3Y6.45%
Revenue growth 5Y4.62%
Revenue growth Q2Q3.61%
Revenue Next Year0.9%
Revenue Next 2Y3.09%
Revenue Next 3Y4.36%
Revenue Next 5Y4.96%
EBIT growth 1Y24.08%
EBIT growth 3Y14.02%
EBIT growth 5Y6.89%
EBIT Next Year18.05%
EBIT Next 3Y12.96%
EBIT Next 5Y8.95%
FCF growth 1Y39.13%
FCF growth 3Y11.98%
FCF growth 5Y8.95%
OCF growth 1Y24.88%
OCF growth 3Y10.91%
OCF growth 5Y7.36%